Checkpoint Inhibitors Market Report 2026

The checkpoint inhibitors market size has grown strongly in recent years. It will grow from $46.27 billion in 2025 to $49.12 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to limited availability of checkpoint inhibitors, reliance on conventional chemotherapy and radiotherapy, increasing incidence of cancers, rising awareness of immunotherapy options, regulatory approvals for first-generation inhibitors.

The checkpoint inhibitors market size is expected to see strong growth in the next few years. It will grow to $63.4 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to launch of novel pd-1, pd-l1, and ctla-4 inhibitors, expansion of car t-cell therapies, growth in combination therapy research, increasing adoption of personalized cancer treatments, rising investment in oncology-focused digital health solutions. Major trends in the forecast period include rising adoption of pd-1 and pd-l1 inhibitors across multiple cancer types, growth in combination therapies with checkpoint inhibitors, expansion of car t-cell therapy in oncology, increasing clinical trials for emerging checkpoint inhibitors, focus on personalized immunotherapy and targeted cancer treatments.

The increasing number of cancer cases worldwide is expected to drive the growth of the checkpoint inhibitors market in the coming years. Cancer comprises a group of diseases marked by the uncontrolled growth and spread of abnormal cells that can invade nearby tissues and spread to other parts of the body. The rise in cancer incidence is driven by factors such as aging populations, unhealthy lifestyle habits including smoking and poor diet, environmental exposures such as pollution and radiation, genetic susceptibility, and infections such as HPV and hepatitis. Checkpoint inhibitors function by blocking proteins that suppress immune cell activity, thereby enabling the immune system to better recognize and destroy cancer cells. For example, in September 2024, according to the American Cancer Society, global cancer cases among men are projected to increase by 84% by 2050, rising from 10.3 million in 2022 to 19 million, while cancer-related deaths are expected to grow by 93%, from 5.4 million to 10.5 million during the same period. Consequently, the rising global incidence of cancer is anticipated to significantly boost demand for checkpoint inhibitors.

Major companies operating in the checkpoint inhibitor market are increasingly focusing on the development of advanced technologies such as oral checkpoint inhibitors to address unmet clinical needs. A large proportion of cancer patients do not respond adequately to existing immune checkpoint inhibitors, driving the need for alternative approaches. Oral checkpoint inhibitors are cancer immunotherapy drugs administered by mouth that target immune checkpoints such as PD-1 and PD-L1, helping activate the immune system against cancer cells. For instance, in September 2024, OmRx Oncology, a US-based biopharmaceutical company, launched OX-4224, an oral checkpoint inhibitor targeting the PD-1/PD-L1 pathway for the treatment of non-small cell lung cancer. This investigational therapy is intended to serve as a more affordable alternative to injectable biologic checkpoint inhibitors, with the goal of expanding global access to immunotherapy. A Phase 2 clinical study in India is evaluating its safety and effectiveness in patients with advanced non-small cell lung cancer, with plans to extend availability to low- and middle-income countries.

In July 2024, Boehringer Ingelheim, a Germany-based pharmaceutical company, acquired Nerio Therapeutics for up to $1.3 billion. Through this acquisition, Boehringer Ingelheim gained access to Nerio’s preclinical checkpoint inhibitor research, which focuses on inhibiting the enzymes PTPN1 and PTPN2 to strengthen immune responses against tumors. Nerio Therapeutics is a US-based biotechnology company specializing in immuno-oncology drug discovery and the development of next-generation immune checkpoint inhibitors.

Major companies operating in the checkpoint inhibitors market are AstraZeneca plc, Bristol-Myers Squibb Company, Merck & Co. Inc., Roche Holding AG, Pfizer Inc., Incyte Corporation, Novartis AG, GlaxoSmithKline plc, Innate Pharma S.A., Ono Pharmaceutical Co. Ltd., Eli Lilly and Company, Sanofi S.A, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bayer AG, Boehringer Ingelheim International GmbH, Celgene Corporation, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Kyowa Kirin Co. Ltd., Johnson & Johnson, Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Zai Lab Limited.

North America was the largest region in the checkpoint inhibitors market in 2025. The Middle East is expected to be the fastest growing region in the global checkpoint inhibitors market share during the forecast period. The regions covered in the checkpoint inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the checkpoint inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the checkpoint inhibitors market by increasing the cost of imported biologics, monoclonal antibodies, and CAR T-cell therapy products. Hospital pharmacies, retail pharmacies, and online pharmacies in North America and Europe, which rely heavily on imports, are most affected. This has led to higher treatment costs and potential delays in patient access. On the positive side, tariffs have encouraged local manufacturing, domestic R&D investment, and innovation in cost-effective immunotherapy solutions.

The checkpoint inhibitors market research report is one of a series of new reports that provides checkpoint inhibitors market statistics, including checkpoint inhibitors industry global market size, regional shares, competitors with a checkpoint inhibitors market share, detailed checkpoint inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the checkpoint inhibitors industry. This checkpoint inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Checkpoint inhibitors refer to an immunotherapy approach that blocks immune checkpoint proteins from interacting with other proteins. By preventing these interactions, T cells are able to attack and destroy cancer cells because the inhibitory “off” signal is not transmitted. One such therapy targets the checkpoint protein CTLA-4.

The primary drug types in checkpoint inhibitors include PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, chimeric antigen receptor T cells, and others. PD-1 and PD-L1 inhibitors are anticancer immunotherapies that block the activity of the immune checkpoint proteins PD-1 and PD-L1 on the cell surface. These therapies are used in the treatment of lung cancer, renal cancer, blood cancer, bladder cancer, melanoma, and others, and are distributed through sectors such as hospital pharmacies, retail pharmacies, and online pharmacies.

The checkpoint inhibitors market consists of sales of atezolizumab, avelumab, and durvalumab. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.